Growth Metrics

Axsome Therapeutics (AXSM) Long-Term Debt Issuances (2023 - 2026)

Axsome Therapeutics' Long-Term Debt Issuances history spans 3 years, with the latest figure at $70.0 million for Q1 2026.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $70.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $210.0 million, a N/A change, with the full-year FY2025 number at $330.0 million, changed N/A from a year prior.
  • Long-Term Debt Issuances hit $70.0 million in Q1 2026 for Axsome Therapeutics, roughly flat from $70.0 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for AXSM hit a ceiling of $70.0 million in Q3 2025 and a floor of $30.0 million in Q2 2023.
  • Historically, Long-Term Debt Issuances has averaged $59.0 million across 3 years, with a median of $70.0 million in 2025.